Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Clinical Trial
[키워드] acute respiratory syndrome
Administered
Adults
adverse event
age
assigned
binding
CD4
chills
conducted
Control
convalescent serum
coronavirus
coronavirus disease
cytokine response
death
dose
dose-dependent
dose-escalation
elicited
ENCODE
fatigue
geometric mean titer
GMT
headache
healthy
immunization
immunogenicity
incidence
include
Infection
Infectious disease
injection
Messenger RNA
Mild
moderate
mRNA-1273
mRNA-1273 vaccine
multiple methods
myalgia
Neutralizing activity
Neutralizing-antibody
neutralizing-antibody titer
Older
Older age
older population
Open-label
Pain
participant
Phase 3
prefusion
Prevent
receive
recipient
reported
response
Result
S-2P
Safety
SARS-CoV-2
SARS-CoV-2 spike protein
serum
severity
stratified
subgroup
Support
T cells
Testing
the median
Trial
type 1 helper
Vaccine
vaccine candidate
vaccine trial
[DOI] 10.1056/NEJMoa2028436 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2028436 PMC 바로가기 [Article Type] Clinical Trial